Cocrystal Pharma Announces New Data on CC-31244 and Abstract Acceptance for Poster Presentation at the AASLD 2019 Liver Meeting
30. Oktober 2019 08:05 ET
|
Cocrystal Pharma, Inc.
New data to be presented from U.S. Phase 2a clinical trial of CC-31244 for ultrashort treatment of hepatitis C virus (HCV)Eight of 12 patients achieved primary endpoint of sustained virologic response...